TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03937687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine+TeaCrine+Dynamine
Description: combination of caffeine, TeaCrine, and Dynamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine
Study: NCT00503568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad100-gp96Ig-HLA A1
Description: Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad100-gp96Ig-HLA A1
Description: Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad100-gp96Ig-HLA A1
Description: Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
Study: NCT00699933

Intervention type: OTHER
Intervention: CT-guided percutaneous drainage technique
Description: Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
Study: NCT03645837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression clamp release
Description: Standard compression clamp is used and will be released at different times according to randomization
Study: NCT03872583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Understanding MRI in MS (website)
Description: Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
Study: NCT04222387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-B scan
Description: OCT-B scan (Optical coherence tomography)
Study: NCT00810303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetrol (ezetimibe) multiple dose
Description: administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose
Description: administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose
Description: administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustiva (efavirenz) single dose
Description: administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
Study: NCT06132321

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
Study: NCT03381430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day oral daily
Study: NCT03583437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate Intensity Exercise (50 % af VO2max) for 90 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
Study: NCT01094171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix TM
Description: Intramuscular administration, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix TM
Description: Intramuscular administration, 3 doses
Study: NCT03301922

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metacognitive therapy and work-focused interventions
Description: Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy and work-focused interventions
Description: Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: Waiting list
Study: NCT01495507

Intervention type: PROCEDURE
Intervention: MPFL- Reconstruction
Study: NCT03872583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control website
Description: Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
Study: NCT03743012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated cardiac rehabilitation
Description: Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
Study: NCT03180190

Intervention type: DRUG
Intervention: Hydroxychloroquine Oral Tablet
Description: slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)

Intervention type: DRUG
Intervention: Hydroxychloroquine Oral Tablet
Description: slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)
Study: NCT04077684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
Study: NCT01322334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing exercises
Description: A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
Study: NCT00776867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
Study: NCT01465061

Intervention type: BEHAVIORAL
Intervention: Online support group
Description: Joining online support group
Study: NCT01087242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tang-min Lin pill
Description: Tang-min Lin pill 6g,tid,treat 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tang-min Lin pill
Description: Tang-min Lin pill 6g,tid,treat 12 weeks.
Study: NCT00715000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy
Description: oral rehydration solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical hydration via intravenous infusion
Description: intravenous infusion
Study: NCT02685514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU Graves
Description: The HIFU treatment technique will be applied to the recruited participants
Study: NCT04053634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Study: NCT03881410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: different types of ultrasound technique
Description: Shear-wave elastography-guided or Convention ultrasound-guided

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different types of ultrasound technique
Description: Shear-wave elastography-guided or Convention ultrasound-guided
Study: NCT03703050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab cohort 1
Description: Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
Study: NCT04077684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interleukin-2
Description: IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
Study: NCT03956173

Intervention type: OTHER
Intervention: Hypoglycemic combined with either normo or hyperglycemic clamp.
Description: Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
Study: NCT03703050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab cohort 2
Description: Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
Study: NCT01453660

Intervention type: OTHER
Intervention: Endo-PAT2000 testing
Description: Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)

Intervention type: OTHER
Intervention: Endo-PAT2000 testing
Description: Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
Study: NCT05179824

Intervention type: OTHER
Intervention: Observation
Description: No Intervention
Study: NCT05349084

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-cCTA-cFFR
Description: patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
Study: NCT02243007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-Paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT01991717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Victus
Description: The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Phaco
Description: The capsulotomy as well as the lens fragmentation is performed manually.
Study: NCT03670381

Intervention type: OTHER
Intervention: Psychiatric diagnosis

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Study: NCT01068054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: 0.1% ointment,apply bid, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporins
Description: 2% eyclosporine eye drops apply 1 drop to each eye QID
Study: NCT02336893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
Study: NCT00104611

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Study: NCT00438971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
Study: NCT03040193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine Nebulization
Description: 4% Lignocaine delivered via Nebulization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nebulization
Description: Normal Saline Delivered via Nebulization
Study: NCT02553941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given intravenous or subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given by mouth once daily
Study: NCT00657774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FlutiForm 250/10 ug
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FlutiForm 100/10 ug
Description: SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Prednisone 10mg
Description: 2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
Study: NCT03436563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1/TGFbetaRII Fusion Protein M7824
Description: Given IV
Study: NCT04133038

Intervention type: OTHER
Intervention: Questionnaire
Description: Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.

Intervention type: OTHER
Intervention: Questionnaire
Description: Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.

Intervention type: OTHER
Intervention: Questionnaire
Description: Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.

Intervention type: OTHER
Intervention: Questionnaire
Description: Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
Study: NCT02151409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
Study: NCT02345642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiveCare+SFT Supine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveCare+SFT Supine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VenaFlow Elite Supine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaFlow Elite Supine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiveCare+SFT Standing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveCare+SFT Standing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VenaFlow Elite Standing
Study: NCT04845373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Diet intervention:Mediterranean diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet: Low fat diet
Description: Low fat diet
Study: NCT03844607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
Study: NCT03673930

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zanthozylum armatum
Description: Zanthozylum armatum MCT oil extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sunflower oil matched for appearance
Study: NCT04540575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NICU Acquires MOM
Description: Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother Provides MOM
Description: Mother receives standard Rush NICU lactation care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Provides MOM
Description: Mother receives standard Rush NICU lactation care
Study: NCT00378105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
Study: NCT04735536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT1812
Description: Active Treatment- CT1812 at a dose of 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT1812
Description: Active Treatment- CT1812 at a dose of 300mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01910571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P7435

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo